Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13048973 | 1.00 | CCR2 (1.00) | CCR2KCNH2 | |
| SCHEMBL14281986 | 1.00 | CCR2 (1.00) | CCR2KCNH2 | |
| SCHEMBL5058152 | 1.00 | CCR2 (1.00) | CCR2KCNH2 | |
| SCHEMBL14264965 | 1.00 | CCR2 (1.00) | CCR2KCNH2 | |
| SCHEMBL5058151 | 1.00 | CCR2 (1.00) | CCR2KCNH2 | |
| SCHEMBL6013676 | 0.97 | CCR2 (1.00) | CCR2KCNH2 | |
| SCHEMBL6013639 | 0.97 | CCR2 (1.00) | CCR2KCNH2 | |
| SCHEMBL6013675 | 0.97 | CCR2 (1.00) | CCR2KCNH2 | |
| SCHEMBL6013624 | 0.96 | CCR2 (0.95) | CCR2KCNH2 | |
| SCHEMBL6013623 | 0.96 | CCR2 (0.95) | CCR2KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 148 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122094689-A | Combination therapy of diacylglycerol kinase (DGK) alpha inhibitors with other therapies | — | 2026-05-26 | — | — | CN | claimed |
| WO-2025051110-A1 | COMBINATIONS TREATMENTS OF DIACYLGLYCEROL KINASE (DGK) ALPHA INHIBITORS AND OTHER THERAPIES | INSILICO MEDICINE IP LIMITED (CN) | 2025-03-13 | — | — | WO | claimed |
| US-20240277684-A1 | BLOCKADE OF CHEMOKINE (C-C MOTIF) RECEPTOR 2 DURING FLUID RESUSCITATION | UNIVERSITY OF SOUTH FLORIDA | 2024-08-22 | — | — | US | claimed |
| US-20230270732-A1 | BLOCKADE OF CHEMOKINE (C-C MOTIF) RECEPTOR 2 DURING FLUID RESUSCITATION | NATIONAL INSTITUTES OF HEALTH | 2023-08-31 | — | — | US | claimed |
| US-8729063-B2 | 3-aminopyrrolidine derivatives as modulators of chemokine receptors | INCYTE CORPORATION (US) | 2014-05-20 | — | — | US | claimed |
| US-20130116230-A1 | 3-AMINOPYRROLIDINE DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTORS | INCYTE CORPORATION (US) | 2013-05-09 | — | — | US | claimed |
| US-8362003-B2 | 3-aminopyrrolidine derivatives as modulators of chemokine receptors | INCYTE CORPORATION (US) | 2013-01-29 | — | — | US | claimed |
| EP-1565436-B1 | 3-AMINOPYRROLIDINE DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTORS | INCYTE CORP (US) | 2012-04-25 | — | — | EP | claimed |
| EP-2431357-A2 | 3-Aminopyrrolidine Derivatives as Modulators of Chemokine Receptors | Incyte Corporation (US) | 2012-03-21 | — | — | EP | claimed |
| US-20110251168-A1 | 3-AMINOPYRROLIDINE DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTORS | INCYTE CORPORATION | 2011-10-13 | — | — | US | claimed |
| US-7985730-B2 | 3-aminopyrrolidine derivatives as modulators of chemokine receptors | INCYTE CORPORATION (US) | 2011-07-26 | — | — | US | claimed |
| US-20090247474-A1 | 3-Aminopyrrolidine Derivatives As Modulators Of Chemokine Receptors | INCYTE CORPORATION | 2009-10-01 | — | — | US | claimed |
| US-20060252751-A1 | 3-Aminopyrrolidine derivaties as modulators of chemokine receptors | INCYTE HOLDINGS CORPORATION | 2006-11-09 | — | — | US | claimed |
| US-20260144674-A1 | Apparatus and Methods for Drug Delivery Using Microneedles | CLEARSIDE BIOMEDICAL, INC. (US) | 2026-05-28 | — | — | US | disclosed |
| CN-122094689-A | Combination therapy of diacylglycerol kinase (DGK) alpha inhibitors with other therapies | — | 2026-05-26 | — | — | CN | disclosed |
| US-20260109747-A1 | Conjugate Comprising an IL-2 Moiety | ASCENDIS PHARMA ONCOLOGY DIV A/S (DK) | 2026-04-23 | — | — | US | disclosed |
| WO-2006073592-A2 | SALTS OF N-[2-({3R)-1-[trans-4-HYDROXY-4-(6-METHOXYPYRIDIN-3-YL)-CYCLOHEXYL]PYRROLIDINE-3-YL}AMINO)-2-OXOETHYL]-3-(TRIFLUOROMETHYL)BENZAMIDE | INCYTE CORPORATION (US) | 2006-07-13 | — | — | WO | disclosed |
| US-20060111404-A1 | Salts of N-[2-({(3R)-1-[trans-4-hydroxy-4-(6-methoxypyridin-3-yl)-cyclohexyl]pyrrolidin-3-yl}amino)-2-oxoethyl]-3-(trifluoromethyl)benzamide | INCYTE CORPORATION | 2006-05-25 | — | — | US | disclosed |
| US-20060111404-A1 | Salts of N-[2-({(3R)-1-[trans-4-hydroxy-4-(6-methoxypyridin-3-yl)-cyclohexyl]pyrrolidin-3-yl}amino)-2-oxoethyl]-3-(trifluoromethyl)benzamide | INCYTE CORPORATION | 2006-05-25 | — | — | US | disclosed |
| US-20060111404-A1 | Salts of N-[2-({(3R)-1-[trans-4-hydroxy-4-(6-methoxypyridin-3-yl)-cyclohexyl]pyrrolidin-3-yl}amino)-2-oxoethyl]-3-(trifluoromethyl)benzamide | INCYTE CORPORATION | 2006-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130116230-A1 | 3-AMINOPYRROLIDINE DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTORS | CCR2, CXCR3, CCR5 | CCR2 1/4885KCNH2 2991/4885 |
| US-20240277684-A1 | BLOCKADE OF CHEMOKINE (C-C MOTIF) RECEPTOR 2 DURING FLUID RESUSCITATION | CCR2, CCR1, CCL2 | CCR2 1/4885KCNH2 3537/4885 |
| US-20260109747-A1 | Conjugate Comprising an IL-2 Moiety | IL2, IL2RA, ILF2 | CCR2 117/4885KCNH2 3144/4885 |
| US-20060252751-A1 | 3-Aminopyrrolidine derivaties as modulators of chemokine receptors | CCR2, CXCR3, CCR5 | CCR2 1/4885KCNH2 2930/4885 |
| US-20260144674-A1 | Apparatus and Methods for Drug Delivery Using Microneedles | PROKR2, SLC10A2, GLP1R | CCR2 1022/4885KCNH2 4557/4885 |
| US-20060111404-A1 | Salts of N-[2-({(3R)-1-[trans-4-hydroxy-4-(6-methoxypyridin-3-yl)-cyclohexyl]pyrrolidin-3-yl}amino)-2-oxoethyl]-3-(trifluoromethyl)benzamide | CCR5, CCR2, ACKR3 | CCR2 2/4885KCNH2 1483/4885 |
| US-20090247474-A1 | 3-Aminopyrrolidine Derivatives As Modulators Of Chemokine Receptors | CCR2, CXCR3, CCR5 | CCR2 1/4885KCNH2 2991/4885 |
| US-20110251168-A1 | 3-AMINOPYRROLIDINE DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTORS | CCR2, CXCR3, CCR5 | CCR2 1/4885KCNH2 2991/4885 |
| US-20230270732-A1 | BLOCKADE OF CHEMOKINE (C-C MOTIF) RECEPTOR 2 DURING FLUID RESUSCITATION | CCR2, CCR1, CCL2 | CCR2 1/4885KCNH2 3537/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.